Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
Background. Triple negative breast cancer has no specific treatment sites for chemotherapy and is unfavorable in terms of prognosis. One of the drugs widely used in this cohort of patients is eribulin, which in addition to its antimitotic effect has an effect on the tumor microenvironment. The searc...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-01-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/895 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399189623013376 |
|---|---|
| author | L. A. Tashireva N. O. Popova V. V. Alifanov V. E. Goldberg E. I. Kovalenko E. V. Artamonova A. G. Manikhas D. M. Ponomarenko N. V. Levchenko E. I. Rossokha S. Yu. Krasilnikova M. A. Zafirova V. M. Perelmuter |
| author_facet | L. A. Tashireva N. O. Popova V. V. Alifanov V. E. Goldberg E. I. Kovalenko E. V. Artamonova A. G. Manikhas D. M. Ponomarenko N. V. Levchenko E. I. Rossokha S. Yu. Krasilnikova M. A. Zafirova V. M. Perelmuter |
| author_sort | L. A. Tashireva |
| collection | DOAJ |
| description | Background. Triple negative breast cancer has no specific treatment sites for chemotherapy and is unfavorable in terms of prognosis. One of the drugs widely used in this cohort of patients is eribulin, which in addition to its antimitotic effect has an effect on the tumor microenvironment. The search for biological criteria that will allow predicting the effectiveness of the drug is assumed relevant since it will help to select patients who may receive the most benefit from certain therapy regimens.Objective: identification of immunological predictors of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic triple-negative breast cancer.Materials and methods. The study included 20 patients with locally advanced and metastatic triple negative breast cancer. 50 % had a short-term response (progression-free survival <3 months) to eribulin therapy, and 50 % had a long-term response (progression-free survival >6 months). Seven-color immunofluorescence was used to determine the subpopulation composition of tumor-infiltrating lymphocytes and their PD1 expression. Image acquisition and analysis were performed using the Vectra® 3.0 system and InForm® software (Akoya Biosciences, USA).Results. It has been shown that the ratio of the number of PD1-negative to PD1-positive CD20+ B-lymphocytes less than 5.5 associated with the long-term effectiveness of eribulin in patients with locally advanced or metastatic triple negative breast cancer.Conclusion. The results showed that the ratio of the number of PD1-negative to PD1-positive CD20+ B-lymphocytes can be considered as a possible marker to predict the effectiveness of eribulin in patients with breast cancer. |
| format | Article |
| id | doaj-art-04fa079dcbd74e2faf1af1a6011b0a93 |
| institution | Kabale University |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2022-01-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-04fa079dcbd74e2faf1af1a6011b0a932025-08-20T03:38:24ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272022-01-01174485510.17650/1994-4098-2021-17-4-48-55715Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot studyL. A. Tashireva0N. O. Popova1V. V. Alifanov2V. E. Goldberg3E. I. Kovalenko4E. V. Artamonova5A. G. Manikhas6D. M. Ponomarenko7N. V. Levchenko8E. I. Rossokha9S. Yu. Krasilnikova10M. A. Zafirova11V. M. Perelmuter12Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of SciencesResearch Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of SciencesResearch Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of SciencesResearch Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of SciencesN.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia;N.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaDepartment of Surgical Oncology No. 1, Saint Petersburg Clinical Oncology DispensaryIrkutsk Regional Oncology Dispensary; Irkutsk State Medical Academy of Postgraduate Education, a branch of Russian Medical Academy of Postgraduate Education, Ministry of Health of RussiaSaint Petersburg Clinical Research and Practical Center for Specialized Medical Care (Oncological), Ministry of Health of RussiaAltai Regional Oncology DispensarySverdlovsk Regional Oncology DispensaryUral State Medical University, Ministry of Health of RussiaResearch Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of SciencesBackground. Triple negative breast cancer has no specific treatment sites for chemotherapy and is unfavorable in terms of prognosis. One of the drugs widely used in this cohort of patients is eribulin, which in addition to its antimitotic effect has an effect on the tumor microenvironment. The search for biological criteria that will allow predicting the effectiveness of the drug is assumed relevant since it will help to select patients who may receive the most benefit from certain therapy regimens.Objective: identification of immunological predictors of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic triple-negative breast cancer.Materials and methods. The study included 20 patients with locally advanced and metastatic triple negative breast cancer. 50 % had a short-term response (progression-free survival <3 months) to eribulin therapy, and 50 % had a long-term response (progression-free survival >6 months). Seven-color immunofluorescence was used to determine the subpopulation composition of tumor-infiltrating lymphocytes and their PD1 expression. Image acquisition and analysis were performed using the Vectra® 3.0 system and InForm® software (Akoya Biosciences, USA).Results. It has been shown that the ratio of the number of PD1-negative to PD1-positive CD20+ B-lymphocytes less than 5.5 associated with the long-term effectiveness of eribulin in patients with locally advanced or metastatic triple negative breast cancer.Conclusion. The results showed that the ratio of the number of PD1-negative to PD1-positive CD20+ B-lymphocytes can be considered as a possible marker to predict the effectiveness of eribulin in patients with breast cancer.https://ojrs.abvpress.ru/ojrs/article/view/895breast cancereribulintumor microenvironment |
| spellingShingle | L. A. Tashireva N. O. Popova V. V. Alifanov V. E. Goldberg E. I. Kovalenko E. V. Artamonova A. G. Manikhas D. M. Ponomarenko N. V. Levchenko E. I. Rossokha S. Yu. Krasilnikova M. A. Zafirova V. M. Perelmuter Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study Опухоли женской репродуктивной системы breast cancer eribulin tumor microenvironment |
| title | Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study |
| title_full | Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study |
| title_fullStr | Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study |
| title_full_unstemmed | Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study |
| title_short | Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study |
| title_sort | microenvironment related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer pilot study |
| topic | breast cancer eribulin tumor microenvironment |
| url | https://ojrs.abvpress.ru/ojrs/article/view/895 |
| work_keys_str_mv | AT latashireva microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT nopopova microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT vvalifanov microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT vegoldberg microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT eikovalenko microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT evartamonova microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT agmanikhas microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT dmponomarenko microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT nvlevchenko microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT eirossokha microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT syukrasilnikova microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT mazafirova microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy AT vmperelmuter microenvironmentrelatedpredictivemarkersofthetherapeuticeffectivenessoferibulininpatientswithlocallyadvancedormetastaticbreastcancerpilotstudy |